Penserra Capital Management LLC Grows Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Penserra Capital Management LLC boosted its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 2,069.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,212 shares of the medical equipment provider's stock after acquiring an additional 12,603 shares during the period. Penserra Capital Management LLC's holdings in Hologic were worth $815,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of HOLX. EverSource Wealth Advisors LLC raised its holdings in shares of Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 260 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after buying an additional 159 shares during the last quarter. Raiffeisen Bank International AG purchased a new stake in shares of Hologic in the fourth quarter valued at about $49,000. West Financial Advisors LLC purchased a new stake in shares of Hologic in the first quarter valued at about $50,000. Finally, Covestor Ltd raised its holdings in shares of Hologic by 49.3% in the fourth quarter. Covestor Ltd now owns 1,033 shares of the medical equipment provider's stock valued at $75,000 after buying an additional 341 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on HOLX shares. Citigroup raised shares of Hologic from a "neutral" rating to a "buy" rating and upped their target price for the company from $60.00 to $80.00 in a report on Wednesday. Morgan Stanley dropped their price target on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Wall Street Zen lowered shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Raymond James Financial reiterated an "outperform" rating and set a $71.00 price target (down from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Finally, Royal Bank Of Canada dropped their price target on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $78.75.

Insider Activity at Hologic

In other Hologic news, Director Martin D. Madaus purchased 5,445 shares of the stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the transaction, the director directly owned 5,445 shares of the company's stock, valued at $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 1.88% of the stock is owned by corporate insiders.

Hologic Price Performance

HOLX traded down $0.94 on Friday, hitting $65.91. 771,847 shares of the company were exchanged, compared to its average volume of 2,993,705. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24. The business's fifty day moving average is $61.32 and its 200 day moving average is $63.59. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.67. The firm has a market capitalization of $14.69 billion, a P/E ratio of 27.82, a price-to-earnings-growth ratio of 2.41 and a beta of 0.55.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The company's quarterly revenue was down 1.2% on a year-over-year basis. During the same period in the prior year, the business earned $1.03 earnings per share. As a group, sell-side analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.